Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, I Saari T. Pharmacol Res Perspect. 2016 Nov 3;4(6):e00271. doi: 10.100…

Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis. Zheng, Wanhong MD; Nickasch, Michael BS; Lander, Laura MSW; Wen, Sijin P…

PRINCETON, N.J. and SOUTH SAN FRANCISCO, Calif. and MONTREAL. Braeburn Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. today announced that three Probuphine presentations were featured at the International Society of Addiction Medici…

A multi-site clinical trial led by researchers at the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated the effectiveness of CAM2038, a potentially transformative buprenorphine therapy for moderate-to-severe opioid u…

Interim Buprenorphine vs. Waiting List for Opioid Dependence. Sigmon SC, Ochalek TA, Meyer AC, Hruska B, Heil SH, Badger GJ, Rose G, Brooklyn JR, Schwartz RP, Moore BA, Higgins ST. N Engl J Med. 2016 Dec 22;375(25):2504-2505. doi: 10.1056/NEJMc161…

The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. Carroll KM, Weiss RD. Am J Psychiatry. 2016 Dec 16:appiajp201616070792. [Epub ahead of print] Abstract https://www.ncbi.nlm.nih.gov/pubmed/27978771